Corporate Ventures Fund of Merck KGaA, Darmstadt, Germany, Creates New Immuno-Oncology Company iOnctura
- iOnctura is set up to develop a pipeline of assets targeting immunosuppression in the tumour microenvironment
- The company will progress its portfolio of assets seamlessly into clinical evaluation, in collaboration with one of its shareholders Cancer Research Technology (CRT)
- The vision of iOnctura is - through combination with its pipeline - to significantly improve the clinical efficacy and expand the utility of checkpoint inhibitors
Darmstadt, Germany, June 20, 2016 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its corporate venture arm created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck KGaA, Darmstadt, Germany, and three assets from Cancer Research Technology (CRT). CRT is the commercial arm of Cancer Research UK, London, UK. The Corporate Ventures Fund of Merck KGaA, Darmstadt, Germany, will manage the investment and will be represented on iOnctura’s board of directors.
“Our goal is to modulate key culprits of immunosuppression in the tumor microenvironment to maximize the therapeutic potential of checkpoint inhibitors for patients,” said Catherine Pickering, CEO and co-founder of iOnctura. “Through our key alliances with CRT and Merck KGaA, Darmstadt, Germany, we are optimally positioned to explore novel combination therapies and advance them quickly to cancer patients.”
iOnctura aims to develop a pipeline of selected assets that target and modulate mechanisms that drive immunosuppression in the tumor microenvironment (TME). Such immunosuppression has been shown to be one of the main causes behind a significant number of patients not responding to first generation checkpoint inhibitors. iOnctura, through its alliances with Merck KGaA, Darmstadt, Germany, and CRT, has already built a pipeline of promising programs and entered a research collaboration with CRT Discovery Laboratories. In exchange for the exclusive global option to license three immuno-oncology assets from CRT, iOnctura will provide CRT with an initial equity holding in the company and will make further payments for the achievement of late development and approval milestones as well as royalties on net sales. iOnctura has also secured access to future supply of avelumab, being co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany, and Pfizer, which will enable acceleration into initial clinical proof of concept studies.
Stuart Farrow, CRT’s director of biology, said: “We’re delighted that these three potential new cancer treatments, partly developed by our drug discovery laboratories alongside leading Cancer Research UK-funded scientists, have been prioritized for further development through the formation of this new company. The ongoing support by our drug discovery laboratories will hopefully help build a strong development pipeline for iOnctura.”
The Corporate Ventures Fund of Merck KGaA, Darmstadt, Germany, is providing the initial seed funding to iOnctura. Hakan Goker, Senior Investment Director at the Corporate Ventures Fund of Merck KGaA, Darmstadt, Germany, and Keno Guttierrez, Investment Director, will represent the Corporate Ventures Fund on iOnctura’s board of directors.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany, generated sales of € 19.7 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Two new strategic drug discovery collaborations aim at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities.